Building on more than 22 years of CDMO experience across biologics and advanced therapies, Northway Biotech is significantly expanding its development and manufacturing capacity with a new 3,500 sq. m facility featuring up to 20 independent cGMP manufacturing lines and first customer programmes already secured.
The first dedicated innovative cell therapy and personalised medicine centre of its kind in the Baltic States has opened in Vilnius, Lithuania, marking a major expansion of Northway Biotech’s CDMO capabilities in advanced therapies. The Northway Group has invested EUR €61 million in the new 3,500m2 facility within the broader BIO CITY III development.
The centre significantly expands Northway Biotech’s established CDMO platform across mammalian and microbial biologics, gene therapy, and cell-based technologies, adding substantial new development and cGMP manufacturing capacity for advanced and personalised therapies. It will support biotechnology and pharmaceutical companies, university hospitals, and research institutions and begins operations with its first customers already on board and contracts in place.
The facility brings together specialised infrastructure and technologies for the development and cGMP manufacturing of autologous and allogeneic cell-based therapies, personalised therapeutic vaccines, regenerative medicine applications, and 3D human tissue technologies. Its segregated manufacturing infrastructure enables multiple cell-based products and processes to be handled in parallel while maintaining stringent requirements for product identity, quality, traceability and contamination control.
